Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$5.52
+0.9%
$4.65
$3.42
$7.20
$307.49M1.941.54 million shs637,942 shs
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$22.69
-5.5%
$20.77
$10.14
$28.42
$284.69M0.8679,500 shs186,714 shs
Cellectis S.A. stock logo
CLLS
Cellectis
$1.41
-3.4%
$1.42
$1.10
$2.81
$78.37M3.11142,784 shs39,491 shs
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
$5.80
-1.2%
$5.95
$1.16
$10.37
$309.96M0.5394,128 shs121,202 shs
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
+0.91%+5.75%+17.95%+7.39%-12.52%
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-5.46%-13.56%+7.89%-4.86%+92.78%
Cellectis S.A. stock logo
CLLS
Cellectis
-3.42%-7.24%-8.44%+6.02%-49.28%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
-1.19%-10.77%-13.56%-11.99%+226.76%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.7954 of 5 stars
0.02.00.00.04.00.80.6
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
4.2909 of 5 stars
4.63.00.04.62.20.80.0
Cellectis S.A. stock logo
CLLS
Cellectis
3.1231 of 5 stars
3.55.00.00.01.92.50.6
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
1.9322 of 5 stars
3.51.00.00.03.20.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
3.22
Buy$41.8684.47% Upside
Cellectis S.A. stock logo
CLLS
Cellectis
3.00
Buy$6.67372.81% Upside
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
3.00
Buy$8.5046.55% Upside

Current Analyst Ratings Breakdown

Latest CLLS, TKNO, ACB, and CDTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$47.00
5/23/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$31.00 ➝ $35.00
5/23/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00
5/16/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$35.00 ➝ $50.00
5/13/2025
Cellectis S.A. stock logo
CLLS
Cellectis
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.00
5/9/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$33.00 ➝ $35.00
5/9/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$46.00 ➝ $47.00
4/29/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$46.00 ➝ $46.00
4/10/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
3/12/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
3/12/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$46.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$320.81M0.97$0.21 per share26.35$8.18 per share0.67
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$302K942.69N/AN/A($1.82) per share-12.47
Cellectis S.A. stock logo
CLLS
Cellectis
$47.63M1.65N/AN/A$1.52 per share0.93
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
$38.25M8.10N/AN/A$2.21 per share2.62
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-$48.62M$0.05110.4212.55N/A0.42%0.59%0.42%6/19/2025 (Estimated)
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$22.93M-$29.47N/AN/AN/A-289.05%-69.64%-33.73%8/11/2025 (Estimated)
Cellectis S.A. stock logo
CLLS
Cellectis
-$101.06M-$0.86N/AN/AN/A-234.39%-74.55%-22.65%8/5/2025 (Estimated)
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
-$36.78M-$0.48N/AN/AN/A-87.17%-35.30%-24.52%N/A

Latest CLLS, TKNO, ACB, and CDTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/19/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11N/AN/AN/A$88.85 millionN/A
5/12/2025Q1 2025
Cellectis S.A. stock logo
CLLS
Cellectis
-$0.1540-$0.18-$0.0260-$0.18$12.71 million$12.03 million
5/8/2025Q1 2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$5.45-$1.66+$3.79-$1.66N/AN/A
5/8/2025Q1 2025
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
-$0.11-$0.09+$0.02-$0.09$9.41 million$9.60 million
3/13/2025Q4 2024
Cellectis S.A. stock logo
CLLS
Cellectis
$0.06-$0.16-$0.22-$0.15$5.90 million$33.22 million
3/6/2025Q4 2024
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$5.28-$5.38-$0.10-$5.37N/AN/A
3/4/2025Q4 2024
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
N/A-$0.11N/A-$0.11$9.10 million$9.27 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/AN/AN/AN/AN/A
Cellectis S.A. stock logo
CLLS
Cellectis
N/AN/AN/AN/AN/A
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.07
3.30
1.60
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/A
3.54
3.54
Cellectis S.A. stock logo
CLLS
Cellectis
0.48
1.78
1.78
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
0.12
4.73
3.94

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
35.82%
Cellectis S.A. stock logo
CLLS
Cellectis
63.90%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
13.81%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
7.64%
Cellectis S.A. stock logo
CLLS
Cellectis
16.41%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
15.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,34056.21 million54.85 millionOptionable
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
9012.55 million6.51 millionNo Data
Cellectis S.A. stock logo
CLLS
Cellectis
29055.58 million46.46 millionOptionable
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
24053.44 million45.21 millionNot Optionable

Recent News About These Companies

BTIG Reaffirms Their Hold Rating on Alpha Teknova (TKNO)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$5.52 +0.05 (+0.91%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$5.56 +0.04 (+0.63%)
As of 05/28/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Cidara Therapeutics stock logo

Cidara Therapeutics NASDAQ:CDTX

$22.69 -1.31 (-5.46%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$21.96 -0.73 (-3.22%)
As of 05/28/2025 06:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Cellectis stock logo

Cellectis NASDAQ:CLLS

$1.41 -0.05 (-3.42%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$1.44 +0.03 (+1.77%)
As of 05/28/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Alpha Teknova stock logo

Alpha Teknova NASDAQ:TKNO

$5.80 -0.07 (-1.19%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$5.89 +0.09 (+1.53%)
As of 05/28/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.